ArticleAllergy2026
Resolving Endoplasmic Reticulum-Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of endoplasmic reticulum stress-related biomarkers in asthma and asthma exacerbation.Frontiers in medicine · 2026Article
- Neutrophil extracellular traps in asthma and chronic obstructive pulmonary disease: pathogenic roles, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPeople with severe steroid-resistant asthma are refractory to treatment with the mainstay inhaled corticosteroids (ICS), emphasising the urgent need for alternative therapies. This study aimed to assess the effect of endoplasmic reticulum stress (ERS) on steroid responsiveness and to evaluate the efficacy of 4-phenylebuteric acid (4-PBA) as an add-on treatment to restore steroid responses in severe asthma.
methodsThe relationship between ERS and steroid response was assessed by treating human airway epithelial cells (AEC) with chemical ERS inducers or TNF, IFN-γ, and IL-17, and assessing the effects of dexamethasone (Dex) and 4-PBA. The correlation between genes associated with ERS and GR-signalling was assessed in sputum cells from patients with severe asthma, and the effects of 4-PBA were assessed in two murine models of severe, steroid-resistant asthma.
resultsChemical ERS inducers significantly downregulated the expression of corticosteroid-responsive genes, HSD11B2 and FKBP5 and reduced GR nuclear translocation in basal AECs. Treatment with TNF, IFN-γ and IL-17 upregulated ERS and protein misfolded markers while reducing Dex-induced GR nuclear translocation. In sputum cells from patients with severe asthma, ERS genes negatively correlated with GR-signalling. In differentiated primary bronchial epithelial cells (pBECs), treatment with 4-PBA reversed TNF, IFN-γ and IL-17-induced steroid resistance by upregulating HSD11B2 and FKBP5 gene expression and downregulating inflammatory genes. 4-PBA together with Dex significantly reduced airway inflammation and/or AHR in experimental models of severe, steroid-resistant asthma.
conclusionWe provide evidence for ERS inducing steroid resistance that underpins severe asthma and demonstrate a therapeutic potential for restoring steroid sensitivity in severe asthma with 4-PBA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.